|
人附睾蛋白4临床应用研究进展
|
Abstract:
[1] | Barbieri, R.L. (2010) In Women Who Have a Pelvic Mass Have You Tried This New Ovarian Cabiomarker? OBG Management, 22, 8-12. |
[2] | Kirchhoff, C., Habben, I., Ivell, R., et al. (1991) A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors. Biology of Reproduction, 45, 350-357.
http://dx.doi.org/10.1095/biolreprod45.2.350 |
[3] | Bingle, L., Singleton, V. and Bingle, C.D. (2002) The Putative Ovarian Tumour Marker Gene HE4 (WFDC2), Is Expressed in Normal Tissues and Undergoes Complex Alternative Splicing to Yield Multiple Protein Isoforms. Oncogene, 21, 2768-2773. http://dx.doi.org/10.1038/sj.onc.1205363 |
[4] | Bingle, L., Cross, S.S., High, A.S., et al. (2006) WFDC2(HE4): A Protential Role in the Innate Immunity of The Oral Cavity and Respiratory Tract and Development of Adenocarcinomas of the Lung. Respiratory Research, 7, 61.
http://dx.doi.org/10.1186/1465-9921-7-61 |
[5] | Gao, L., Cheng, H.Y., Dong, L., et al. (2011) The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis. Journal of International Medical Research, 39, 1645-1660.
http://dx.doi.org/10.1177/147323001103900507 |
[6] | Clauss, A., Ng, V., Liu, J., et al. (2010) Over Expression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains And Activation of the Nuclear Factor Kappa B Pathway And Is Associated with Poor Overall Surviva. Neoplasia, 12, 161-172. http://dx.doi.org/10.1593/neo.91542 |
[7] | Lin, Y., Bai, L., Chen, W., et al. (2010) The NF kappaB Activation Pathways, Emerging Molecular Targets for Cancer Prevention and Therapy. Expert Opinion on Therapeutic Targets, 14, 45-55.
http://dx.doi.org/10.1517/14728220903431069 |
[8] | Galgano, M.T., Hampton, G.M., Frierson Jr., H.F. (2006) Comprehensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. http://dx.doi.org/10.1038/modpathol.3800612 |
[9] | Karlsen, N.S., Karlsen, M.A., Hogdall, C.K., et al. (2014) HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. Cancer Epidemiology, Biomarkers & Prevention, 23, 2285-2295. http://dx.doi.org/10.1158/1055-9965.EPI-14-0447 |
[10] | Moore, R.G., Brown, A.K., Miller, M.C., et al. (2008) The Use of Multiple Novel Tumor Biomarkers for the Detection of Ovarian Carcinoma in Patients with Pelvic Mass. Gynecologic Oncology, 108, 402-408.
http://dx.doi.org/10.1016/j.ygyno.2007.10.017 |
[11] | Holcomb, K., Vucetic, Z., Miller, M.C., et al. (2011) Human Epididymis Protein 4 Offers Superior Specificity in the Differentiation of Benign and Malignant Adnexal Masses in Premenopausal Women. American Journal of Obstetrics & Gynecology, 205, 358-366. http://dx.doi.org/10.1016/j.ajog.2011.05.017 |
[12] | Karisen, M.A., Sandhu, N., Hogdall, C., et al. (2012) Evaluation of HE4, CA125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) as Diagnostic Tools of Epithelial Ovarian Cancer in Patients with a Pelvic Mass. Gynecologic Oncology, 127, 379-383. http://dx.doi.org/10.1016/j.ygyno.2012.07.106 |
[13] | FDA (2014) US Foodand Drug Administration. http://fda.gov |
[14] | 王瑞红. 人附睾分泌蛋白4和CA125对卵巢癌的联合诊断价值[J]. 国际检验医学杂志, 2014, 35(1): 103-104. |
[15] | 刘倩, 郭健. HE4 和 CA125 监测老年卵巢癌转归的价值[J]. 标记免疫分析与临床, 2011, 18(6): 374-379. |
[16] | 石华, 罗蔚, 李文胜, 等. 血清人附睾上皮分泌蛋白水4平检测在卵巢癌的应用价值[J]. 实用妇产科杂志, 2015, 31(4): 267-269. |
[17] | 程洪艳, 刘亚南, 叶雪, 等. 血清人附睾分泌蛋白4(HE4)和CA125在卵巢癌患者手术及化疗前后的变化[J]. 中国妇产科临床杂志, 2011, 12(3): 212-215. |
[18] | 蔡斌, 刘雪莲, 杨懿霞, 等. 913例健康体检女性血清HE4水平分布的初步观察[J]. 实用妇产科杂志, 2012, 28(12): 1045-1049. |
[19] | 刘静, 曲芃芃. ROMA指数在卵巢癌诊断中临床价值的Meta分析[J]. 实用妇产科杂志, 2015, 31(3): 209-213. |
[20] | 王坤, 玉萍, 郭亚琼. ROMA指数在卵巢恶性肿瘤诊断中的应用价值[J]. 标记免疫分析与临床, 2015, 22(7): 666-668. |
[21] | 高岚, 许泼实, 张福明. 血清HE4、CA-125及ROMA指数在卵巢癌诊断中的价值评价[J]. 医药论坛杂志, 2015, 36(9): 8-9. |
[22] | 邓拥军, 郭秋霞. HE4、CA-125、ROMA联合应用诊断卵巢良性与恶性肿瘤的作用[J]. 湖北中医药大学学报, 2015, 17(1): 102-104. |
[23] | 雅培. 中国人群卵巢癌风险评估进展[R]. 全国检验医师大会, 2013. |
[24] | Jemal, A., Siegel, R. and Xu, J. (2010) Cancer Statistics. CA: A Cancer Journal for Clinicians, 60, 277-300.
http://dx.doi.org/10.3322/caac.20073 |
[25] | Molina, J.R., Yang, P., Cassivi, S.D., et al. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factor, Treatment, and Survivorship. Mayo Clinic Proceedings, 83, 584-594. http://dx.doi.org/10.1016/S0025-6196(11)60735-0 |
[26] | Mulshine, J.L. and Sullivan, D.C. (2005) Clinical Practice Lung Cancer Screening. The New England Journal of Medicine, 352, 2714-2720. http://dx.doi.org/10.1056/NEJMcp042630 |
[27] | Yamashita, S., Tokuishi, K., Hashimoto, T., et al. (2011) Prognostic Significance of HE4 Expression in Pulmonary Adenocarcinoma. Tumor Biology, 32, 265-271. http://dx.doi.org/10.1007/s13277-010-0118-5 |
[28] | Iwahori, K., Suzuki, H., Kishi, Y., et al. (2012) Serum HE4 as a Diagnostic and Prognostic Marker for Lung Cancer. Tumor Biology, 33, 1141-1149. http://dx.doi.org/10.1007/s13277-012-0356-9 |
[29] | Tokuishi, K., Yamashita, S., Ohbo, K., et al. (2012) Splice Variant HE4-V3 Expression Is Associated with Favorable Prognosis in Pulmonary Adenocarcinoma. Tumor Biology, 33, 103-109. http://dx.doi.org/10.1007/s13277-011-0252-8 |
[30] | 肖然, 胡昊昀, 王瑞, 等. 血清肿瘤标志物 HE4 检测在肺癌诊断中的应用价值探讨[J]. 检验医学, 2014, 29(9): 893-896. |
[31] | 于飞, 王倩, 钟殿胜, 等. 血清人附睾蛋白 4 检测对肺癌的诊断意义[J]. 天津医药, 2014, 42(2): 116-118. |
[32] | 薛霞, 杨凡, 单咏梅, 等. 血清人附睾蛋白4检测在肺癌诊断中的意义[J]. 实用检验医师杂志, 2013, 5(2): 96-98. |
[33] | Elsammak, M.Y., Attia, A., Hassan, H.A., et al. (2012) Evaluation of Pleural Fluid Human Epididymis 4 (HE4) as a Marker of Malignant Pleural Effusion. Tumor Biology, 33, 1701-1707. http://dx.doi.org/10.1007/s13277-012-0427-y |
[34] | Hegmans, J.P., Veltman, J.D., Fung, E.T., et al. (2009) Protein Profiling of Pleural Effusions to Identify Malignant Pleural Mesothelioma Using SELDI-TOF MS. Technology in Cancer Research & Treatment, 8, 323-332.
http://dx.doi.org/10.1177/153303460900800502 |